【产品介绍】：

中文别名 托珠单抗 英文别名 Tocilizumab CAS号 375823-41-9 SMILES Inchi InchiKey 分子式 Formula 144984.63 分子量 Molecular Weight C6428H9976N1720O2018S42 闪点 FP NA 熔点 Melting point NA 沸点 Boiling point NA Polarizability极化度 密度 Density NA 蒸汽压 Vapor Pressure 溶解度Solubility 性状 Liquid 储藏条件 Storage conditions -80°C for long term Protocol Cell Experiment Cell lines non-small cell lung cancer (NSCLC) cells (A549, H460, H358 and H1299 cells) Preparation method Ten microliters of tocilizumab, MTX or 5-FU are added to 96-well plates containing 104 cells per well in 100 µl medium. The final concentrations of tocilizumab are 10, 100 and 1000 ng/ml. The final concentrations of MTX and 5-FU are 50 and 25 µg/ml, respectively. Following a 24-h incubation, WST-1 solution is added, and the optical density is analyzed at reference wavelengths of 450 and 620 nm. Concentrations 10, 100 and 1000 ng/ml Incubation time 24 h Animal Experiment Animal models Male CB17/ICR-scid/scid mice (SCID mice) Formulation PBS Dosages 100 μg Administration i.p. Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines) Species Mouse Rat Rabbit Guinea pig Hamster Dog Weight (kg) 0.02 0.15 1.8 0.4 0.08 10 Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5 Km factor 3 6 12 8 5 20 Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km Animal A Km For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg. Tocilizumab使用注意事项： 1.实验前需戴好防护眼镜，穿戴防护服和口罩，佩戴手套，避免与皮肤接触。 2.实验过程中如遇到有毒或者刺激性物质及有害物质产生，必要时实验操作需要手套箱内完成以免对实验人员造成伤害。 3.取样品的移液枪头需及时更换，必要时为避免交叉污染尽可能选择滤芯吸头。 4.称量药品时选用称量纸，并无风处取药和称量以免扬撒，试剂的容器使用前务必确保干净，并消毒。 5.取药品时尽量采用多个药勺分别使用，使用后清洗干净。 6.实验后产生的废弃物需分类存储，并交于专业生物废气物处理公司处理，以免造成环境污染。 大规格定制：定制产品请将信息发送至sales@bio-fount.com。 Experimental considerations: 1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment. 2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution. 产品说明 Organic Acids IntroductionDaratumumab is a monoclonal antibody that targets and induces apoptosis in cells that highly express CD38, including multiple myeloma cells.6,7It has a long duration of action as it is given every 1-4 weeks.6,7Patients should be counselled regarding the risk of hypersensitivity, neutropenia, thrombocytopenia, embryo-fetal toxicity, and interferences with cross-matching and red blood cell antibody screening.6,7 Application1Interleukin 6 (IL-6) is a pro-inflammatory cytokine produced by cells including T-cells, B-cells, lymphocytes, monocytes, fibroblasts.6IL-6 rapidly induces C-reactive protein, serum amyloid A, fibrinogen, haptoglobin, and α-1-antichymotrypsin while inhibiting production of fibronectin, albumin, and transferrin.4IL-6 also induces antibody production, induces cytotoxic T-cell differentiation, and inhibits regulatory T-cell differentiation.4Tocilizumab binds soluble and membrane bound IL-6 receptors, preventing IL-6 mediated inflammation.6TargetActionsOrganismAInterleukin-6 receptor subunit alphainhibitorantibodyHumans Application2 Application3 In vitro: Tocilizumab inhibits the binding of IL-6 to its receptors, and thus reduces the cytokines pro-inflammatory activity by competing for both the soluble and membrane-bound forms of the human IL-6 receptor. The inhibitory profile of anti-IL-6R mAb Tocilizumab is independent of membrane-bound IL-6R expression. Tocilizumab has anticancer potency via apoptosis induction as an agonistic IL-6R regulator. It has also been demonstrated that tocilizumab has an anti-proliferative effect on glioma cells via inhibition of the JAK-STAT3 pathway. Tocilizumab exhibits a significant growth inhibition in NSCLC cells (H460, A549, H1299 and H358), with proliferation significantly decreased by approximately 40% in A549 cells. Tocilizumab does not alter the levels of the ERK1/2, STAT3, NFκB and phosphorylated ERK1/2 and STAT3 proteins, but this antibody does considerably increase the expression of phosphorylated NFκB in NSCLC cells. Tocilizumab significantly inhibits expression of both IL-8 and MMP-9, known as the major angiogenic factors. In vivo: A series of clinical studies has shown that inhibition of IL-6 signaling by tocilizumab is therapeutically effective in rheumatoid arthritis, juvenile idiopathic arthritis, Castleman's disease, and Crohn's disease. In all of these diseases, tocilizumab ameliorates inflammatory manifestations, and normalizes acute phase protein levels. Tocilizumab as a monotherapy and in combination, such as with methotrexate in case of rheumatoid arthritis, seems to be well tolerated. Tocilizumab markedly decreases the number of invaded capillary vessels in tumors. 警示图 危险性 危险性警示 warning 安全声明 安全防护 备注 实验过程中防止吸入、食如，做好安全防护 Rapid deterioration in a patient with primary aggressive cutaneous epidermotropic CD8+ cytotoxic T-cell ('Berti') lymphoma after administration of adalimumab. Jacks SM, et al. J Am Acad Dermatol. 2014 1、Rapid deterioration in a patient with primary aggressive cutaneous epidermotropic CD8+ cytotoxic T-cell ('Berti') lymphoma after administration of adalimumab. Jacks SM, et al. J Am Acad Dermatol. 2014 Sep;71(3):e86-7. PMID: 25128139. 2、Adalimumab prevents barrier dysfunction and antagonizes distinct effects of TNF-α on tight junction proteins and signaling pathways in intestinal epithelial cells. Fischer A, et al. Am J Physiol Gastrointest Liver Physiol. 2013 Jun 1;304(11):G970-9. PMID: 23538493. 对不起，暂无产品评价！